The T-box transcription factor family member TBX3 has been demonstrated to participate in the development of various types of cancer, including head and neck squamous cell carcinoma. However, little is currently known about its role in hypopharyngeal carcinoma. In the present study, the involvement of TBX3 in hypopharyngeal carcinoma was investigated. Immunohistochemical assays revealed that TBX3 levels were increased in hypopharyngeal carcinoma compared with normal tissue samples, accompanied by upregulated N-cadherin and downregulated E-cadherin. Lentivirus-mediated TBX3 knockdown efficiently suppressed its expression and inhibited the proliferation of FaDu cells. The opposite was observed in TBX3-overexpressing FaDu cells. These results indicate that TBX3 is essential for FaDu cell proliferation. Furthermore, TBX3 silencing led to a disturbance of the cell cycle, leading to a decrease in the G 1 phase and an increase in the S phase. In addition, apoptosis was enhanced following TBX3 knockdown. The present results suggest TBX3 as a potential therapeutic target in hypopharyngeal carcinoma.
Introduction
Hypopharyngeal carcinoma, which originates in the mucosal epithelia of the hypopharynx, accounts for 5% of head and neck cancer cases worldwide (1) (2) (3) . Once diagnosed, this disease has limited treatment options and a poor prognosis (4) . Despite the combination of surgery, radiotherapy and chemotherapy benefiting the patients, the overall 5-year survival rate remains <20% (5) (6) (7) . Therefore, there is a constant need to develop novel and effective therapeutic targets for hypopharyngeal carcinoma.
The T-box transcription factor family, which comprises TBX1, TBX2 and TBX3, serves an important role in embryonic development. TBX3 is widely expressed in various tissues and is associated with the pluripotency of embryonic stem cells (8) (9) (10) . Overexpression of this protein has been demonstrated to be associated with various types of cancer, including breast cancer (11) , gastric cancer (12) , colorectal cancer (13) , bladder cancer (14) , head and neck cancer (15) and melanoma (16) . Ectopic TBX3 expression promotes the growth and invasion of gastric cancer (12) . Mechanistically, TBX3 accelerates papillary thyroid carcinoma cell proliferation by potentiating polycomb repressive complex 2-mediated cyclin-dependent kinase (CDK) inhibitor 1C (p57KIP2) repression. It also drives the growth of sarcoma by suppressing CDK inhibitor 1 (p21) (17) . In addition, TBX3 is targeted by microRNA (miR)-17-92 and miR-206, contributing to their suppressive role in pancreatic and breast cancer stem cell viability (18, 19) . These findings suggest that targeting TBX3 may be helpful in treating patients with cancer. However, the role of this factor in hypopharyngeal carcinoma remains largely unclear.
In the present study, TBX3 was identified as a potential oncogene in hypopharyngeal carcinoma. Its upregulation was observed in hypopharyngeal carcinoma samples when compared with normal tissue samples. The silencing of TBX3 caused cell cycle arrest at the S phase and increased apoptosis, potentially contributing to the suppressed proliferation of TBX3-knockdown hypopharyngeal carcinoma FaDu cells. By contrast, ectopic TBX3 expression led to an increased
TBX3 knockdown suppresses the proliferation of hypopharyngeal carcinoma FaDu cells by inducing G1/S cell cycle arrest and apoptosis
viability of FaDu cells. Therefore, this transcription factor maybe a promising target for the treatment and monitoring of hypopharyngeal carcinoma. exact test. Spearman's correlation test was also used. A Mann-Whitney U test was applied to analyze the immunohistochemistry results. P<0.05 was considered to indicate a statistically significant difference.
Materials and methods
TBX3 expression -------------------------- Clinical
Results
TBX3 is highly expressed in cancer tissues of patients with hypopharyngeal cancer. In order to assess the clinical relevance of TBX3 in hypopharyngeal carcinoma, an immunohistochemistry assay was performed to investigate the expression of TBX3 in hypopharyngeal cancer tissue and normal hypopharyngeal specimens in the present study. The association between the expression of TBX3 and clinicopathological factors in patients with hypopharyngeal carcinoma is demonstrated in Table I . The results revealed that TBX3 protein levels were significantly increased in hypopharyngeal carcinoma compared with the normal hypopharyngeal tissues ( Fig. 1A ; Table II ). Furthermore, the expression of N-cadherin and E-cadherin was examined in hypopharyngeal carcinoma and normal hypopharyngeal tissues. The results demonstrated a higher expression of N-cadherin and lower expression of E-cadherin in hypopharyngeal carcinoma tissues compared with the normal hypopharyngeal tissues ( Fig. 1B and C ; Table II ). Further analysis revealed a negative correlation between TBX3 and E-cadherin (r 2 =-0.389; P=0.034; Table III ). Collectively, these data indicate that TBX3 is a potential biomarker for hypopharyngeal carcinoma and may be essential for the progression of this disease.
TBX3 promotes hypopharyngeal carcinoma cell proliferation. TBX3 was upregulated in hypopharyngeal carcinoma specimens, but whether it is associated with the progression of hypopharyngeal carcinoma remains less clear. In order to address this question, TBX3 was knocked-down and overexpressed in hypopharyngeal carcinoma FaDu cells, using lentivirus-based shRNA and overexpressing strategies, respectively. Green fluorescence data demonstrated that the infection efficiency was similar between the shCtrl and shTBX3 ( Fig. 2A) . RT-qPCR and western blotting results verified that TBX3 was efficiently knocked-down in the FaDu cells (Fig. 2B ). In addition, TBX3 was efficiently overexpressed (Fig. 2C) . The upregulation of E-cadherin, p57KIP2 and p21 was observed, as well as the downregulation of N-cadherin in the shTBX3 group compared with shCtrl FaDu cells (Fig. 2D ).
The inverse results were observed in the TBX3-overexpressed cells ( Fig. 2E) . Subsequently, the effect of TBX3 on hypopharyngeal carcinoma cell proliferation was examined. The results of the MTT assay demonstrated that although no significant inhibition was observed on days 1 and 2, TBX3 silencing notably inhibited the proliferation of FaDu cells on days 3-5 (Fig. 2F) . By contrast, TBX3 ectopic expression promoted cell proliferation (Fig. 2G) . Taken together, the results from the present study demonstrate that TBX3 silencing inhibited the proliferation of hypopharyngeal carcinoma cells, indicating that this protein is critical for hypopharyngeal carcinoma cell viability.
TBX3 silencing induces cell cycle arrest in FaDu cells.
Accelerated cell cycle progression is one of the main reasons that cancer cells proliferate at a higher rate than normal cells (21) . The cell cycle progression in shCtrl-and shTBX3-transfected FaDu cells was investigated in the present study. Decreased G 1 and increased S phase distribution were exhibited in shTBX3 FaDu cells compared with shCtrl cells, whereas no significant change was observed in the distribution of cells in the G 2 /M phase (Fig. 3A and B) , indicating that the cell cycle was arrested at the S phase in the shTBX3-transfected FaDu cells. Furthermore, the expression of cell cycle proteins was investigated. The western blotting results revealed that CDK2, CDK4, PCNA and cyclin E expression was decreased, whereas p27 was upregulated in the shTBX3 FaDu cells (Fig. 3C) . Taken together, the data from the present study demonstrated that TBX3 silencing in FaDu cells results in enhanced cell cycle arrest.
TBX3 silencing enhances the apoptosis rate of FaDu cells.
The present study then determined whether TBX3 regulates the apoptosis rate of FaDu cells. The apoptosis rate of cells transfected with shCtrl and shTBX3 was analyzed using Annexin V-APC staining and flow cytometry. TBX3 knockdown led to an increase in the apoptosis rate of the FaDu cells ( Fig. 4A and B) . The expression of cleaved-caspase 3, caspase 3 and PARP was increased, whereas Bcl-2 was downregulated following TBX3 knockdown (Fig. 4C) . These results suggest that the induction of apoptosis may contribute to suppressed cell viability in shTBX3-transfected FaDu cells.
Discussion
Although hypopharyngeal carcinoma is a relatively rare disease among the different types of head and neck cancer, it is often diagnosed when it has already reached a malignant stage (22) . Treatment strategies remain ineffective against this fatal disease (22) . In the last decade, certain studies have identified proto-oncogenes and tumor suppressors in hypopharyngeal carcinoma, including c-Myc (23), PI3K-mTOR (24) and phosphate and tensin homolog (PTEN) (25); however, the molecular mechanisms underlying the progression of hypopharyngeal carcinoma are currently poorly understood. Therefore, identifying novel targets triggering hypopharyngeal carcinoma may assist the development of effective targeted treatments. The transcription factor TBX3, which belongs to the T-box family, is involved in the development of multiple organs, including the breast, lung and pancreas (26) . Numerous studies have demonstrated that TBX3 participates in the development of different types of human cancer. For example, TBX3 serves as a downstream effector of Wnt/β-catenin signaling in liver cancer growth (27) . TBX3 is overexpressed in head and neck squamous cell carcinoma and represses the expression of PTEN, which is a common tumor suppressor in various types of cancer (15) . Notably, TBX3 also functions as a downstream target of AKT serine/threonine kinase 3. Upregulation of TBX3 is observed in melanoma tissues and contributes to the growth and invasion of melanoma (28) . At the molecular level, cell adhesion molecule E-cadherin has been reported to be inhibited by TBX3 (29, 30) . E-cadherin is also regulated by hepatocyte growth factor and serves as a prognostic factor for hypopharyngeal carcinoma (31) . However, the association between TBX3 and E-cadherin in hypopharyngeal carcinoma remains unclear. In the present study, the involvement of TBX3 in hypopharyngeal carcinoma was investigated. First, TBX3 was observed to be significantly upregulated in hypopharyngeal carcinoma tissues, whereas E-cadherin was downregulated. In addition, N-cadherin expression was enhanced in these tissues. This suggests that TBX3 may contribute to the progression of hypopharyngeal carcinoma. TBX3 expression was then knocked-down in FaDu cells, which are widely used to study hypopharyngeal carcinoma, using shRNA, leading to decreased cell proliferation. By contrast, TBX3 ectopic expression led to enhanced viability of the cells. Furthermore, E-cadherin and N-cadherin were negatively and positively regulated by TBX3, respectively, which was consistent with the results from the patient samples in the present study. However, certain limitations remained in the present study. As it was not possible to obtain another hypopharyngeal carcinoma cell line, the functional experiments of TBX3 were not investigated in other cells. Further studies should be performed when another hypopharyngeal carcinoma cell line becomes available. Overall, the results from the present study indicate that TBX3 is a potential oncogene in hypopharyngeal carcinoma.
It has been demonstrated that TBX3 is regulated by cyclin A-CDK2 and c-Myc, and is important for S-phase progression (32) . p21, a CDK inhibitor, is transcriptionally repressed by TBX3 (17) . These results suggest that TBX3 is critical for the cell cycle process. In the present study, TBX3 silencing led to an increased number of cells at the S phase of the cell cycle, and a decreased proportion at the G 1 phase, while the cells at the G 2 /M phase remained unchanged. Increasing evidence supports the important role that CDK2, CDK4, cyclin E and p27 serve in cell cycle progression (33) (34) (35) (36) . AsTBX3 was demonstrated to regulate the cell cycle progression of FaDu cells, the present study then detected whether cell cycle-associated proteins were modulated by TBX3. In the FaDu cells, CDK2, CDK4 and cyclin E were repressed following TBX3 knockdown. By contrast, p27 was upregulated by TBX3 silencing. In addition, TBX3 has been reported to regulate apoptosis via various mechanisms. This transcription factor disturbs the p53 pathway to suppress apoptosis, leading to dysregulated cell transformation and myogenic differentiation (37) . TBX3 also serves as an anti-apoptotic protein in mesangial cells (38) . Consistent with these results, enhanced apoptosis was observed in the TBX3-knockdown FaDu cells in the present study. Cleaved-caspase 3, PARP and Bcl-2 are markers of apoptosis. Dysregulation of these genes results in the apoptosis of cancer cells (39, 40) . The present study then determined whether TBX3 regulated the expression of these proteins. The results revealed that cleaved-caspase 3 and PARP were upregulated, whereas the survival marker Bcl-2 was downregulated in the TBX3-silenced cells. Therefore, the results of the present study were consistent with previous studies on TBX3 in cell cycle and apoptosis regulation (41) .
In conclusion, the present study provided evidence to suggest that TBX3 acts as a potential oncogene in hypopharyngeal carcinoma. Elevated TBX3 expression was observed in a cohort of hypopharyngeal carcinoma samples. Furthermore, the knockdown of TBX3 largely inhibited the proliferation of hypopharyngeal carcinoma FaDu cells and led to cell cycle arrest at the S phase and the induction of apoptosis. Therefore, targeting TBX3 may be a promising targeted strategy for hypopharyngeal carcinoma.
